Skip to content

US · MTVA · BIOTECHNOLOGY

MetaVia Inc. (MTVA) intrinsic value and stock valuation

$1.01as of 2026-11-21 · Mkt cap 3.28M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MetaVia Inc. DCF and intrinsic value

InvestorsCraft values MTVA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MTVA’s statements →

MetaVia Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02138 metaviatx.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-12.97M
20142025
Free cash flow
-$-15.7M
20142025
Total equity
$5.33M-5.8% 5y CAGRd
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-13.71M-$-28.81M-$-15.89M-$-19.63M-$-15.3M
Net income-$-12.97M-$-27.59M-$-12.47M-$-13.97M-$-15.28M
EPSd-$-7.33M-$-38.86M-$-27.11M-$-465.67M-$-1.53B
Operating cash flow-$-15.7M-$-24.71M-$-10.8M-$-11.71M-$-15.13M
Capital expenditure-$0.00-$-10K-$-50K$0.00-$0.00
Free cash flow-$-15.7M-$-24.72M-$-10.85M-$-11.71M-$-15.14M
Total assets$69.1M$16.3M$22.8M$33.5M$16.8M
Total debt$210K$140K$200K$0.00$70K
Net debt-$-10.07M-$-15.88M-$-22.23M-$-33.36M-$-16.32M
Total equity$5.33M$7.93M$16.7M$21.8M$14.6M
Cash and short-term investments$10.3M$16M$22.4M$33.4M$16.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$20K$20K$10K$30K$70K
Gross profit-$-20K-$-20K-$-10K-$-30K-$-70K
Research and development expenses$6.8M$21.5M$9.16M$2.78M$6.55M
Selling, general and administrative expenses$6.89M$7.26M$6.73M$8.64M$8.75M
Other expenses$0.00$20K$0.00$8.21M$0.00
Operating expenses$13.7M$28.8M$15.9M$19.6M$15.3M
Cost and expenses$13.7M$28.8M$15.9M$19.6M$15.3M
Interest income$510K$920K$460K$0.00$10K
Interest expense$0.00$0.00$0.00$2.19M$0.00
Depreciation and amortization$20K$20K$10K$20K$50K
Ebitda-$-12.95M-$-27.57M-$-12.46M-$-11.76M-$-15.24M
Operating income-$-13.71M-$-28.81M-$-15.89M-$-19.63M-$-15.3M
Total other income/expenses, net$730K$1.22M$3.42M$5.66M$10K
Income before tax-$-12.97M-$-27.59M-$-12.47M-$-13.97M-$-15.28M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-12.97M-$-27.59M-$-12.47M-$-13.97M-$-15.28M
Weighted average shares outstanding$1.77M$710K$460K$30K$10K
Weighted average diluted shares outstanding$1.77M$710K$460K$30K$10K
Balance sheet
20252024202320222021
Cash and short-term investments$10.3M$16M$22.4M$33.4M$16.4M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$10.9M$16.1M$22.5M$33.5M$16.6M
Property, plant and equipment, net$230K$170K$250K$0.00$210K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$58.3M$190K$270K$0.00$210K
Total assets$69.1M$16.3M$22.8M$33.5M$16.8M
Accounts payable$1.06M$3.88M$820K$710K$830K
Short-term debt$70K$80K$70K$0.00$30K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$5.65M$8.27M$5.96M$11.8M$2.16M
Long-term debt$140K$60K$140K$0.00$40K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$58.1M$60K$140K$0.00$40K
Capital lease obligations$140K$140K$200K$0.00$40K
Total liabilities$63.8M$8.33M$6.1M$11.8M$2.2M
Common stock$0.00$10K$10K$30K$0.00
Retained earnings-$-148.83M-$-135.86M-$-108.27M-$-95.8M-$-81.83M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.33M$7.93M$16.7M$21.8M$14.6M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$210K$140K$200K$0.00$70K
Net debt-$-10.07M-$-15.88M-$-22.23M-$-33.36M-$-16.32M
Cash flow statement
20252024202320222021
Net income-$-12.97M-$-27.59M-$-12.47M-$-13.97M-$-15.28M
Depreciation and amortization$20K$20K$10K$20K$50K
Stock-based compensation$410K$540K$220K$850K$660K
Change in working capital-$-2.93M$2.62M$4.4M-$-1.17M-$-580K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.82M$3.06M$110K-$-200K-$-1.16M
Net cash provided by operating activities-$-15.7M-$-24.71M-$-10.8M-$-11.71M-$-15.13M
Investments in property, plant and equipment-$0.00-$-10K-$-50K$0.00-$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$0.00-$-10K-$-50K$10K-$-590K
Common stock issued$9.98M$20M-$-80K$32.3M$24M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$9.96M$18.3M-$-80K$28.7M$22M
Net change in cash-$-5.74M-$-6.42M-$-10.93M$17M$6.3M
Cash at end of period$10.3M$16M$22.4M$33.4M$16.4M
Operating cash flow-$-15.7M-$-24.71M-$-10.8M-$-11.71M-$-15.13M
Capital expenditure-$0.00-$-10K-$-50K$0.00-$0.00
Free cash flow-$-15.7M-$-24.72M-$-10.85M-$-11.71M-$-15.14M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MetaVia Inc.

        Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.

        CEO
        Hyung Heon Kim
        Employees
        8
        Beta
        0.97

        Explore

        Frequently asked questions

        What is the intrinsic value of MetaVia Inc. (MTVA)?

        InvestorsCraft does not currently publish an intrinsic value for MTVA. How the IC value is calculated.

        Is MTVA undervalued?

        InvestorsCraft does not publish an undervaluation signal for MTVA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.